Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis
Barbara D. Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I. Coleman · 2024
Read Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis by Barbara D. Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I. Coleman (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11677308.txt.
Description
Barbara D Alexander and co-authors chart antifungal treatment changes in a serious lung infection in a 2024 United States claims study. Invasive aspergillosis is a fungal infection that preys on weak immune systems. Doctors often must change drugs mid-course because of side effects, interactions, or poor response. The team followed 1,192 adults from their first hospital stay.
Nearly sixty percent changed therapy at some point. Most changes were dose or form tweaks, while others stopped and restarted later or switched at once. Triazole drugs led every treatment line, above all voriconazole. Amphotericin B use grew in later lines. Among the forty percent who never changed, most took a single triazole. The authors say change is the norm in this care.
Catalog record
| CREATOR | Barbara D. Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I. Coleman |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |